Selected research
Industry Research
Viral Gene Therapy Industry Research Report 2026
Market perspective
The global Viral Gene Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Viral Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Viral Gene Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Viral Gene Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Viral Gene Therapy include AnGes, Catalent, Ionis Pharmaceuticals, Orchard Therapeutics, Sarepta Therapeutics, SIBIONO, Spark Therapeutics, Amgen and Biogen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Viral Gene Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Viral Gene Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Viral Gene Therapy Market by Company
AnGes
Catalent
Ionis Pharmaceuticals
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Amgen
Biogen
Gilead Sciences
Lonza
Novartis
Shanghai Sunway Biotech
Viral Gene Therapy Segment by Type
Integrating Viral Vectors
Non-Integrating Viral Vectors
Viral Gene Therapy Segment by Application
Ophthalmologic Diseases
Hematologic Diseases
Cardiovascular Diseases
Muscular Diseases
Metabolic Diseases
Infectious Diseases
Others
Viral Gene Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Integrating Viral Vectors
- Non-Integrating Viral Vectors
Applications
- Ophthalmologic Diseases
- Hematologic Diseases
- Cardiovascular Diseases
- Muscular Diseases
- Metabolic Diseases
- Infectious Diseases
- Others
Companies covered
- AnGes
- Catalent
- Ionis Pharmaceuticals
- Orchard Therapeutics
- Sarepta Therapeutics
- SIBIONO
- Spark Therapeutics
- Amgen
- Biogen
- Gilead Sciences
- Lonza
- Novartis
- Shanghai Sunway Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Viral Gene Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Integrating Viral Vectors
- 2.2.3 Non-Integrating Viral Vectors
- 2.3 Viral Gene Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Ophthalmologic Diseases
- 2.3.3 Hematologic Diseases
- 2.3.4 Cardiovascular Diseases
- 2.3.5 Muscular Diseases
- 2.3.6 Metabolic Diseases
- 2.3.7 Infectious Diseases
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Viral Gene Therapy Breakdown Data by Type
- 3.1 Global Viral Gene Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Viral Gene Therapy Forecasted Market Size by Type (2027-2032)
4 Viral Gene Therapy Breakdown Data by Application
- 4.1 Global Viral Gene Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Viral Gene Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Viral Gene Therapy Market Perspective (2021-2032)
- 5.2 Global Viral Gene Therapy Growth Trends by Region
- 5.2.1 Global Viral Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Viral Gene Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Viral Gene Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Viral Gene Therapy Market Dynamics
- 5.3.1 Viral Gene Therapy Industry Trends
- 5.3.2 Viral Gene Therapy Market Drivers
- 5.3.3 Viral Gene Therapy Market Challenges
- 5.3.4 Viral Gene Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Viral Gene Therapy Players by Revenue
- 6.1.1 Global Top Viral Gene Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Viral Gene Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Viral Gene Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Viral Gene Therapy Head Office and Area Served
- 6.4 Global Viral Gene Therapy Players, Product Type & Application
- 6.5 Global Viral Gene Therapy Manufacturers Established Date
- 6.6 Global Viral Gene Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Viral Gene Therapy Market Size (2021-2032)
- 7.2 North America Viral Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Viral Gene Therapy Market Size by Country (2021-2026)
- 7.4 North America Viral Gene Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Viral Gene Therapy Market Size (2021-2032)
- 8.2 Europe Viral Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Viral Gene Therapy Market Size by Country (2021-2026)
- 8.4 Europe Viral Gene Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Viral Gene Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Viral Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Viral Gene Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Viral Gene Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Viral Gene Therapy Market Size (2021-2032)
- 10.2 South America Viral Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Viral Gene Therapy Market Size by Country (2021-2026)
- 10.4 South America Viral Gene Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Viral Gene Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Viral Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Viral Gene Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Viral Gene Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AnGes
- 12.1.1 AnGes Company Information
- 12.1.2 AnGes Business Overview
- 12.1.3 AnGes Revenue in Viral Gene Therapy Business (2021-2026)
- 12.1.4 AnGes Viral Gene Therapy Product Portfolio
- 12.1.5 AnGes Recent Developments
- 12.2 Catalent
- 12.2.1 Catalent Company Information
- 12.2.2 Catalent Business Overview
- 12.2.3 Catalent Revenue in Viral Gene Therapy Business (2021-2026)
- 12.2.4 Catalent Viral Gene Therapy Product Portfolio
- 12.2.5 Catalent Recent Developments
- 12.3 Ionis Pharmaceuticals
- 12.3.1 Ionis Pharmaceuticals Company Information
- 12.3.2 Ionis Pharmaceuticals Business Overview
- 12.3.3 Ionis Pharmaceuticals Revenue in Viral Gene Therapy Business (2021-2026)
- 12.3.4 Ionis Pharmaceuticals Viral Gene Therapy Product Portfolio
- 12.3.5 Ionis Pharmaceuticals Recent Developments
- 12.4 Orchard Therapeutics
- 12.4.1 Orchard Therapeutics Company Information
- 12.4.2 Orchard Therapeutics Business Overview
- 12.4.3 Orchard Therapeutics Revenue in Viral Gene Therapy Business (2021-2026)
- 12.4.4 Orchard Therapeutics Viral Gene Therapy Product Portfolio
- 12.4.5 Orchard Therapeutics Recent Developments
- 12.5 Sarepta Therapeutics
- 12.5.1 Sarepta Therapeutics Company Information
- 12.5.2 Sarepta Therapeutics Business Overview
- 12.5.3 Sarepta Therapeutics Revenue in Viral Gene Therapy Business (2021-2026)
- 12.5.4 Sarepta Therapeutics Viral Gene Therapy Product Portfolio
- 12.5.5 Sarepta Therapeutics Recent Developments
- 12.6 SIBIONO
- 12.6.1 SIBIONO Company Information
- 12.6.2 SIBIONO Business Overview
- 12.6.3 SIBIONO Revenue in Viral Gene Therapy Business (2021-2026)
- 12.6.4 SIBIONO Viral Gene Therapy Product Portfolio
- 12.6.5 SIBIONO Recent Developments
- 12.7 Spark Therapeutics
- 12.7.1 Spark Therapeutics Company Information
- 12.7.2 Spark Therapeutics Business Overview
- 12.7.3 Spark Therapeutics Revenue in Viral Gene Therapy Business (2021-2026)
- 12.7.4 Spark Therapeutics Viral Gene Therapy Product Portfolio
- 12.7.5 Spark Therapeutics Recent Developments
- 12.8 Amgen
- 12.8.1 Amgen Company Information
- 12.8.2 Amgen Business Overview
- 12.8.3 Amgen Revenue in Viral Gene Therapy Business (2021-2026)
- 12.8.4 Amgen Viral Gene Therapy Product Portfolio
- 12.8.5 Amgen Recent Developments
- 12.9 Biogen
- 12.9.1 Biogen Company Information
- 12.9.2 Biogen Business Overview
- 12.9.3 Biogen Revenue in Viral Gene Therapy Business (2021-2026)
- 12.9.4 Biogen Viral Gene Therapy Product Portfolio
- 12.9.5 Biogen Recent Developments
- 12.10 Gilead Sciences
- 12.10.1 Gilead Sciences Company Information
- 12.10.2 Gilead Sciences Business Overview
- 12.10.3 Gilead Sciences Revenue in Viral Gene Therapy Business (2021-2026)
- 12.10.4 Gilead Sciences Viral Gene Therapy Product Portfolio
- 12.10.5 Gilead Sciences Recent Developments
- 12.11 Lonza
- 12.11.1 Lonza Company Information
- 12.11.2 Lonza Business Overview
- 12.11.3 Lonza Revenue in Viral Gene Therapy Business (2021-2026)
- 12.11.4 Lonza Viral Gene Therapy Product Portfolio
- 12.11.5 Lonza Recent Developments
- 12.12 Novartis
- 12.12.1 Novartis Company Information
- 12.12.2 Novartis Business Overview
- 12.12.3 Novartis Revenue in Viral Gene Therapy Business (2021-2026)
- 12.12.4 Novartis Viral Gene Therapy Product Portfolio
- 12.12.5 Novartis Recent Developments
- 12.13 Shanghai Sunway Biotech
- 12.13.1 Shanghai Sunway Biotech Company Information
- 12.13.2 Shanghai Sunway Biotech Business Overview
- 12.13.3 Shanghai Sunway Biotech Revenue in Viral Gene Therapy Business (2021-2026)
- 12.13.4 Shanghai Sunway Biotech Viral Gene Therapy Product Portfolio
- 12.13.5 Shanghai Sunway Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst